Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Claudia P. Arevalo, Marcus J. Bolton, Valerie Le Sage, et al.
Science (2022) Vol. 378, Iss. 6622, pp. 899-904
Open Access | Times Cited: 199
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Muriel Aguilar-Bretones, Ron A. M. Fouchier, Marion Koopmans, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 1
Open Access | Times Cited: 80
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 56
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 54
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 48
Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance
Marc Struelens, Catherine Ludden, Guido Werner, et al.
Frontiers in Science (2024) Vol. 2
Open Access | Times Cited: 17
Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats
Jin Tian, Jiumeng Sun, Dongyan Li, et al.
Cell Reports (2022) Vol. 39, Iss. 11, pp. 110969-110969
Open Access | Times Cited: 47
Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Sunate Chuenkitmongkol, Rontgene Solante, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 9, pp. 1255-1268
Open Access | Times Cited: 37
A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety
Md. Aminul Islam
Infectious Medicine (2023) Vol. 2, Iss. 4, pp. 247-261
Open Access | Times Cited: 23
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity
Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112888-112888
Open Access | Times Cited: 21
Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants
Zi-Sin Yang, Tzong-Shiun Li, Yu-Sung Huang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Use of a risk assessment tool to determine the origin of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
Xin Chen, Fatema Kalyar, Abrar Ahmad Chughtai, et al.
Risk Analysis (2024) Vol. 44, Iss. 8, pp. 1896-1906
Open Access | Times Cited: 7
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
William N. Voss, Michael L. Mallory, Patrick O. Byrne, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101668-101668
Open Access | Times Cited: 7
Oral Immunisation With Non‐GMO Surface Displayed SARS‐CoV‐2 Spike Epitopes on Bacteria‐Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice
Robie Vasquez, Ji Hoon Song, Remilyn M. Mendoza, et al.
Microbial Biotechnology (2025) Vol. 18, Iss. 1
Open Access
New insights into gold nanoparticles in virology: A review of their applications in the prevention, detection, and treatment of viral infections
Hossein Teimouri, Shiva Taheri, Fatemeh Eivazzadeh Saidabad, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117844-117844
Open Access
Evaluation of Genomic Surveillance of SARS-CoV-2 Virus Isolates and Comparison of Mutational Spectrum of Variants in Bangladesh
Abeda Sultana, Laila Anjuman Banu, Mahmud Hossain, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 182-182
Open Access
SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods
Giulia Berno, Lavinia Fabeni, Giulia Matusali, et al.
Pathogens (2022) Vol. 11, Iss. 9, pp. 1058-1058
Open Access | Times Cited: 28
ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner
Ayana Isobe, Yasuha Arai, Daisuke Kuroda, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 26
SARS-CoV-2 and male infertility: from short- to long-term impacts
Pei Dai, Fei Qiao, Yi-shuan Elaine Chen, et al.
Journal of Endocrinological Investigation (2023) Vol. 46, Iss. 8, pp. 1491-1507
Open Access | Times Cited: 18
Comorbidities of COVID-19 Patients
Radu Silaghi‐Dumitrescu, Iulia Patrascu, Maria Lehene, et al.
Medicina (2023) Vol. 59, Iss. 8, pp. 1393-1393
Open Access | Times Cited: 17
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 14
Peripheral helper T cells in human diseases
Xueyang Zou, Feifei Huo, Lulu Sun, et al.
Journal of Autoimmunity (2024) Vol. 145, pp. 103218-103218
Open Access | Times Cited: 5
Antivirals for Broader Coverage against Human Coronaviruses
Mia Outteridge, Christine M. Nunn, Kevin M. Devine, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 156-156
Open Access | Times Cited: 4
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations
Roman S. Tumskiy, Anastasiia V. Tumskaia, Iraida Nikolaevna Klochkova, et al.
Computers in Biology and Medicine (2022) Vol. 153, pp. 106449-106449
Open Access | Times Cited: 24
SARS-CoV-2 variants: Impact on biological and clinical outcome
Shakuntala Mahilkar, Sachee Agrawal, Sakshi Chaudhary, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top